Abstract
A significant percentage (40%‐70%) of patients with implantable cardioverter defibrillators (ICDs) receive adjunctive antiarrhythmic drug therapy, although this percentage is presently decreasing. The most common aims of drug therapy in ICD patients are to reduce the number of ventricular arrhythmic events triggering the device, to prolong ventricular tachycardia cycle length and to increase efficacy of antitachycardia pacing, to treat combined supraventricular tachycardias and avoid inappropriate shocks, and to decrease defibrillation energy requirements. However, some antiarrhythmic agents may increase the defibrillation threshold (DFT) and/or the pacing thresholds, may slow the tachycardia below the limit for rate detection, and may cause proarrhythmia. Amiodarone is particularly useful in patients with arrhythmia storm but may increase DFTs in some patients. Follow‐up and appropriate device programming of patients with ICDs is particularly necessary in patients with combined antiarrhythmic drug therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
